Table 1

Summary of cases

Patient	Age/sex	HAART	Duration of HAART (months)	Baseline CD4+ (cell ×10⁶/l)	CD4+ at CMO diagnosis	Anterior chamber inflammation: LCFM (ph/ms)	Ophthalmological findings	Anti-CMV therapy
1	42/M	stavudine				R: 22.6	IR R	IV then oral GCV
		lamivudine	12	5	180	L: 5.1	CMO
		indinavir					Vitritis +
2	29/M	stavudine				R: 82.0	IR both eyes	Oral GCV
		lamivudine	18	4	109	L: 55.3	CMO both eyes
		ritonavir					Vitritis ++ both eyes
3	43/M	stavudine				R: 39.0	IR both eyes	IV GCV
		lamivudine	18	3	146	L: 21.2	CMO both eyes
		saquinavir					Vitritis ++ both eyes
4	32/F	stavudine				R: 3.0	IR L	IVT GCV
		lamivudine	9	9	99	L: 20.1	CMO L
		indinavir					Vitritis ++ L
5	30/M	Zidovudine				ND	IR both eyes	Oral GCV
		zalcitabine	12	3	639		CMO both eyes
		ritonavir
6	34/M	stavudine				R: 5.3	IR L	IVT GCV
		lamivudine	17	4	280	L: 28.3	CMO L
		indinavir					Vitritis ++
7	48/M	stavudine				R: 38.0	IR both eyes	IV GCV
		lamivudine	12	20	100	L: 29.5	CMO both eyes
		saquinavir					Vitritis ++ both eyes
8	39/M	stavudine				ND	IR both eyes	IV GCV
		lamivudine	16	5	175		CMO both eyes
		indinavir					Vitritis ++ both eyes
9	53/M	stavudine				R: 3.6	IR L	NONE
		lamivudine	18	1	144	L: 18.5	CMO L
		indinavir					Vitritis + L

HAART = highly active antiretroviral therapy; IR = inactive retinitis; ND = not determined; CMO = cystoid macular oedema; IV = intravenous; IVT = intravitreal; GCV = ganciclovir; LCFM = laser cell flare meter; ph/ms = photons per millisecond.

Cystoid macular oedema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy

Ophthalmology Jobs